Penetrance, cancer incidence and survival in HFE haemochromatosis-A population-based cohort study
- PMID: 38263707
- DOI: 10.1111/liv.15797
Penetrance, cancer incidence and survival in HFE haemochromatosis-A population-based cohort study
Abstract
Background and aims: Haemochromatosis is characterized by progressive iron overload affecting the liver and can cause cirrhosis and hepatocellular carcinoma. Most haemochromatosis patients are homozygous for p.C282Y in HFE, but only a minority of individuals with this genotype will develop the disease. The aim was to assess the penetrance of iron overload, fibrosis, hepatocellular carcinoma and life expectancy.
Methods: A total of 8839 individuals from the Austrian region of Tyrol were genotyped for the p.C282Y variant between 1997 and 2021. Demographic, laboratory parameters and causes of death were assessed from health records. Penetrance, survival, and cancer incidence were ascertained from diagnosed cases, insurance- and cancer registry data. Outcomes were compared with a propensity score-matched control population.
Results: Median age at diagnosis in 542 p.C282Y homozygous individuals was 47.8 years (64% male). At genotyping, the prevalence of iron overload was 55%. The cumulative penetrance of haemochromatosis defined as the presence of provisional iron overload was 24.2% in males and 10.5% in females aged 60 years or younger. Among p.C282Y homozygotes of the same ages, the cumulative proportion of individuals without fibrosis (FIB-4 score < 1.3) was 92.8% in males and 96.7% in females. Median life expectancy was reduced by 6.8 years in individuals homozygous for p.C282Y when compared with population-matched controls (p = .001). Hepatocellular carcinoma incidence was not significantly higher in p.C282Y homozygotes than in controls matched for age and sex.
Conclusion: Reduced survival and the observed age-dependent increase in penetrance among p.C282Y homozygotes call for earlier diagnosis of haemochromatosis to prevent complications.
Keywords: FIB-4; fibrosis; hepatocellular carcinoma; iron overload; malignancy.
© 2024 The Authors. Liver International published by John Wiley & Sons Ltd.
Similar articles
-
Genetic modifiers of penetrance to liver endpoints in HFE hemochromatosis: Associations in a large community cohort.Hepatology. 2022 Dec;76(6):1735-1745. doi: 10.1002/hep.32575. Epub 2022 Jun 17. Hepatology. 2022. PMID: 35567766 Free PMC article.
-
Hepatocellular carcinoma and the penetrance of HFE C282Y mutations: a cross sectional study.BMC Gastroenterol. 2005 Jun 1;5:17. doi: 10.1186/1471-230X-5-17. BMC Gastroenterol. 2005. PMID: 15929796 Free PMC article.
-
Iron-overload-related disease in HFE hereditary hemochromatosis.N Engl J Med. 2008 Jan 17;358(3):221-30. doi: 10.1056/NEJMoa073286. N Engl J Med. 2008. PMID: 18199861
-
Clinical penetrance in hereditary hemochromatosis: estimates of the cumulative incidence of severe liver disease among HFE C282Y homozygotes.Genet Med. 2018 Apr;20(4):383-389. doi: 10.1038/gim.2017.121. Epub 2017 Aug 3. Genet Med. 2018. PMID: 28771247 Free PMC article. Review.
-
Factors influencing disease phenotype and penetrance in HFE haemochromatosis.Hum Genet. 2010 Sep;128(3):233-48. doi: 10.1007/s00439-010-0852-1. Epub 2010 Jul 6. Hum Genet. 2010. PMID: 20607553 Review.
Cited by
-
Iron and Liver Disease.Adv Exp Med Biol. 2025;1480:237-252. doi: 10.1007/978-3-031-92033-2_16. Adv Exp Med Biol. 2025. PMID: 40603795 Review.
-
Prevention of liver cancer in the era of next-generation antivirals and obesity epidemic.Hepatology. 2025 Jan 14:10.1097/HEP.0000000000001227. doi: 10.1097/HEP.0000000000001227. Online ahead of print. Hepatology. 2025. PMID: 39808821 Free PMC article.
-
Hemochromatosis-How Not to Overlook and Properly Manage "Iron People"-A Review.J Clin Med. 2024 Jun 23;13(13):3660. doi: 10.3390/jcm13133660. J Clin Med. 2024. PMID: 38999226 Free PMC article. Review.
-
New Insights into Aspirin's Anticancer Activity: The Predominant Role of Its Iron-Chelating Antioxidant Metabolites.Antioxidants (Basel). 2024 Dec 29;14(1):29. doi: 10.3390/antiox14010029. Antioxidants (Basel). 2024. PMID: 39857363 Free PMC article. Review.
References
REFERENCES
-
- EASL clinical practice guidelines on haemochromatosis. J Hepatol. 2022;77(2):479-502.
-
- Girelli D, Busti F, Brissot P, Cabantchik I, Muckenthaler MU, Porto G. Hemochromatosis classification: update and recommendations by the BIOIRON society. Blood. 2022;139(20):3018-3029.
-
- Pilling LC, Tamosauskaite J, Jones G, et al. Common conditions associated with hereditary haemochromatosis genetic variants: cohort study in UK biobank. BMJ. 2019;364:k5222.
-
- Ellervik C, Birgens H, Tybjaerg-Hansen A, Nordestgaard BG. Hemochromatosis genotypes and risk of 31 disease endpoints: meta-analyses including 66,000 cases and 226,000 controls. Hepatology. 2007;46(4):1071-1080.
-
- Powell LW, Seckington RC, Deugnier Y. Haemochromatosis. Lancet. 2016;388(10045):706-716.
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous